marked.bio

BCR-ABL/KIT TKI · small molecule

imatinib

2 active trials across 6 of our biomarkers, targeting BCR-ABL/KIT. Not approved for any biomarker on marked.bio yet.

Also known as STI571, Gleevec, Glivec.

Counts only trials that select patients by one of the biomarkers on marked.bio, not every trial of this drug.

Biomarkers

BiomarkerActive trialsAll trialsFurthest active phase
ALK fusion 1 2 Phase 2
BRAF V600E 1 1 Phase 2
BRCA1/2 mutation 1 1 Phase 2
EGFR exon 19 deletion / L858R 1 1 Phase 2
KRAS G12D 1 1 Phase 1
ROS1 fusion 1 1 Phase 2

Trials

2 of 3 trials shown

  1. PLATFORM Study of Precision Medicine for Rare Tumors

    Recruiting Phase 2 Cancer Institute and Hospital, Chinese Academy of Medical Sciences Started 2020Primary completion 2026-07 NCT04423185

    aumolertinibdacomitinib FDA EUalectinibcrizotinibpyrotinibimatinibniraparibpalbociclibvemurafenibsintilimabatezolizumab

    when obtaining EGFR mutation, ALK fusion, ROS-1 fusion, C-MET amplification, C-MET mutation, BRAF mutation, BRCA1/2 mu…

    EGFR exon 19 deletion / L858RBRAF V600EBRCA1/2 mutationALK fusionROS1 fusionRare Tumor

  2. Imatinib and Trametinib for KRAS-mutated Solid Tumor

    Recruiting Phase 1 China Medical University Hospital Started 2025Primary completion 2028-03 NCT06962254

    imatinibtrametinib

    Imatinib and Trametinib for KRAS-mutated Solid Tumor

    KRAS G12DSolid Tumor Cancer